Additional Information
Market:ASX
Sector:Pharma & Biotech
EPIC:MLA
Latest Price: 0.01  (-7.69% Descending)
52-week High:0.03
52-week Low:0.01
Market Cap:5.45M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Medical Australia Full Medical Australia profile here

Medical Australia (ASX: MLA) is engaged in the development, manufacture and distribution of a range of medical devices. The company is focused on five clinical therapy areas within the broader medical devices market – intravenous (IV) systems, safety (injection, collection, destruction), blood banking, surgical products and anaesthesia products.

Pdf

Medical Australia boosts FY2012 revenue by A$1.5m with new supply agreements

Tuesday, November 22, 2011 by Angela Kean
New supply contracts indicate the strong organic revenue growth Medical Australia is experiencing across the business and with further prospects the company is on a solid growth footing for FY2012 and beyond. New supply contracts indicate the strong organic revenue growth Medical Australia is experiencing across the business and with further prospects the company is on a solid growth footing for FY2012 and beyond.

Medical Australia (ASX: MLA) has secured a number of new product supply contracts worth $1.5 million in annualised revenue for the 2012 financial year.

Chief executive officer Mark Donnison said Medical Australia’s reputation in the domestic healthcare market continues to strengthen.

“Building our domestic supply contracts is an important growth driver for Medical Australia and these new agreements reflect the strong organic revenue growth we are experiencing across the business,” he said. 

“Medical Australia’s reputation in the domestic healthcare market continues to strengthen and our reputation as a trusted product supply partner is growing.”

The new contracts include:

- A new product supply agreement with one of Australia’s largest private hospital operators, Healthscope, initially for period of one year (in addition to a contract announced in April 2011);
- A contract to supply intravenous consumables and surgical irrigation products to Epworth Private Hospital on a rolling basis;
- A supply agreement with Vic Ambulance to provide lifesaving intravenous consumables;
- A contract to supply new innovative burette technology to Concord Repatriation and General Hospital; and
- Product supply arrangements with Melbourne Health (17 hospitals), Austin and Repatriation Hospitals (2 hospitals), Eastern Health (3 hospitals), Saint Vincent’s and Mercy Private Group (3 hospitals), and Cabrini Health Group Network (6 hospitals).

Medical Australia has also secured smaller supply agreements with Mater South Brisbane, Princess Margaret Hospital in Western Australia, Mater North Sydney, Macquarie University Teaching Hospital, North Middlesex NHS Trust in the UK, and NSW Ambulance.

The company has also recently shipped a $120,000 second order of specially designed needle cutters to UNICEF.

“We are very encouraged by our relationship with UNICEF and the brand recognition this will create for Medical Australia,” Donnison said. “Internationally, UNICEF is currently utilising our needle cutter product and the feedback has been very positive.”


Growth Prospects

Donnison said Medical Australia has significant organic growth prospects through new product developments, supply agreements, international expansion, and new and original equipment manufacturer agreements.

“The organic growth prospects place MLA on a solid growth footing for FY2012 and beyond.”



Cash Position

At the end of the September quarter Medical Australia had $1.29 million cash.



Record Revenue


Last month the company reported record revenue of $3 million for the first quarter of the 2012 financial year, which included $250,000 worth of sales booked to Medical Australia’s MediVet distributor in the United Kingdom.

The improved first quarter performance was driven by revenue contributions from original equipment manufacturing agreements secured in the previous financial year, and new domestic supply agreements with large public and private healthcare groups in Australia.

Donnison said it has been an encouraging start to the 2012 financial year. “This has been a pleasing start to the year. Sales continue to grow and we are witnessing improved margin performance on our supply contracts in the domestic market.”

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.